Glyree-M 2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, facilitating better glucose uptake by muscle tissues. The prolonged-release formulation ensures a sustained therapeutic effect, promoting improved glycemic control with reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glyree-M 2 Forte is prescribed as an adjunct to diet and exercise to achieve optimal blood sugar regulation in patients inadequately controlled by monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to and during treatment, as metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Caution is advised in patients with hepatic dysfunction, cardiovascular disease, or conditions predisposing to hypoxia. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and adjust dosage accordingly. Patients should be educated on recognizing signs of hypoglycemia and maintaining adherence to prescribed dietary and exercise regimens.